3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: Effect of 6,7-disubstitution on potency and tissue selectivity

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4990-5000

  De Tullio, Pascal ^a   Boverie, Stéphane ^a   Becker, Bénédicte ^b   Antoine, Marie Hélène ^b   Nguyen, Quynh Anh ^b   Francotte, Pierre ^a   Counerotte, Stéphane ^a   Sebille, Sophie ^a   Pirotte, Bernard ^a   Lebrun, Philippe ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 7 METHOXY 4H 1,2,4 THIADIAZINE 1,1 DIOXIDE DERIVATIVE; 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE DERIVATIVE; 6 CHLORO 7 FLUORO 3 ISOPROPYLAMINO 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 7 CHLORO 3 ISOPROPYLAMINO 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 7 FLUORO 3 ISOPROPYLAMINO 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ADENOSINE TRIPHOSPHATE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; DIAZOXIDE; INSULIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; FLUOROMETRY; IN VITRO STUDY; INHIBITION KINETICS; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; RADIOISOTOPE DIAGNOSIS; RAT; SUBSTITUTION REACTION; VASCULAR RING;

ADENOSINE TRIPHOSPHATE; ANIMALS; AORTA; BENZOTHIADIAZINES; CYCLIC S-OXIDES; INSULIN; ION CHANNEL GATING; ISLETS OF LANGERHANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; ORGAN SPECIFICITY; POTASSIUM CHANNELS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22744438406     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0580050     Document Type: Article

References (56)

1. + channels in cardiac muscle. Nature 1983, 305, 147-148.
2. + channels in pancreatic B-cells. Nature 1984, 377, 271-273.
3. + channel. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9816-9820.
4. + channels in arterial smooth muscle. Science 1989, 245, 177-180.
5. + channels in mammalian skeletal muscle cells. Eur. J. Pharmacol. 1993, 236, 419-426.
6. Quayle, J. M.; Nelson, M. T.; Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 1997, 77, 1165-1232.
7. Bryan, J.; Aguilar-Bryan, L. The ABCs of ATP-sensitive potassium channels: more pieces of the puzzle. Curr. Opin. Cell Biol. 1997, 9, 553-559.
8. + channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
9. ATP channels. Annu. Rev. Physiol. 1998, 60, 667-687.
10. + channel openers. Mol. Pharmacol. 1999, 56, 308-315.
11. Seino, S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 1999, 61, 337-362.
12. ATP: an inward rectifier subunit plus a sulfonylurea receptor. Science 1995, 270, 1166-1170.
13. + channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP. Mol. Pharmacol. 1999, 55, 832-840.
14. + channels plays a crucial role in the control of insulin secretion. Pflueger's Arch. 1989, 414, S115-S120.
15. Lebrun, P. Flux cationiques dans les cellules B des îlots pancréatiques et investigations pharmacologiques (Cationic flux in B-cells from pancreatic islets and pharmacological investigations). Rev. Fr. Endocrinol. Clin., Nutr. Metab. 1993, 34, 241-254.
16. Kolb, H. A. Potassium channels in excitable and non-excitable cells. Rev. Physiol. Biochem. Pharmacol. 1990, 15, 51-79.
17. ATP channels in vascular smooth muscles. Clin. Exp. Pharmacol. Physiol. 2002, 29, 312-316.
18. + channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
19. Cotzee, W. A. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc. 1992, 6, 201-208.
20. ATP channel openers: structure-activity relationships and therapeutic potential. Med. Res. Rev. 2004, 24, 213-266.
21. Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent development in the biology and medicinal chemistry of potassium channel modulators: update from a decade progress. J. Med. Chem. 2001, 44, 1627-1653.
22. Lebrun, P.; Devreux, V.; Hermann, M.; Herchuelz, A. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets. J. Pharmacol. Exp. Ther. 1989, 250, 1011-1018.
23. + channels? Trends Pharmacol. Sci. 1993, 14, 332-337.
24. Atwal, K. S. Advances in the structure-activity relationships, mechanism of action, and therapeutic utilities of ATP-sensitive potassium channel openers. Drug Dev. Res. 1994, 33, 250-262.
25. Gribble, F. M.; Reimann, F. Pharmacological modulation of K(ATP) channels. Biochem. Soc. Trans. 2002, 30, 333-339.
26. Sebille, S.; de Tullio, P.; Boverie, S.; Antoine, M.-H.; Lebrun, P.; Pirotte, B. Recent development in the chemistry of potassium channel activators: the cromakalim analogues. Curr. Med. Chem. 2004, 11, 1213-1222.
27. Manley, P. W.; Quast, U. Structure-activity studies of potassium channel opening in pinacidil-types cyanoguanidines, nitroethenediamines, thioureas, and ureas. J. Med. Chem. 1992, 35, 2327-2340.
28. Pirotte, B.; Fontaine, J.; Lebrun, P. Recent advances in the chemistry of potassium channel openers. Curr. Med. Chem. 1995, 2, 537-582.
29. Björk, E.; Berne, C.; Kämpe, O.; Wibell, P.; Oskarsson, P.; Karlsson, F. A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996, 45, 1427-1430.
30. Alemzadeh, R.; Langley, G.; Upchurch, L.; Smith, P.; Slonim, A. E. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. Endocrinol. Metab. 1998, 83, 1911-1915.
31. Rasmussen, S. B.; Sorensen, T. S.; Hansen, J. B.; Mandrup-Poulsen, T.; Hornum, L.; Markholst, H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cells function and mass in acutely diabetic BB rats. Horm. Metab. Res. 2000, 32, 294-300.
32. Cosgrove, K.; Antoine, M.-H.; Lee, A.; Barnes, P.; de Tullio, P.; Clayton, P.; McCloy, R.; De Lonlay, P.; Nihoul-Fékété, C.; Robert, J.; Saudubray, J.-M.; Rahier, J.; Lindley, K.; Hussain, K.; Aynsley-Green, A.; Pirotte, B.; Lebrun, P.; Dunne, M. BPDZ 154 activates adenosine 5′-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J. Clin. Endcrinol. Metab. 2002, 87, 4860-4868.
33. Kumar, G. K.; Dastoor, F. C.; Robayo, J. R.; Razzaque, M. A. Side effects of diazoxide. JAMA, J. Am. Med. Assoc. 1976, 235, 275-276.
34. de Tullio, P.; Pirotte, B.; Lebrun, P.; Fontaine, J.; Dupont, L.; Antoine, M.-H.; Ouedraogo, R.; Khelili, S.; Maggetto, C.; Masereel, B.; Diouf, O.; Podona, T.; Delarge, J. 3- and 4-substituted 4H-pyrido[4,3-e]-1,2,4- thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation and structure-activity relationships. J. Med. Chem. 1996, 39, 937-948.
35. de Tullio, P.; Ouedraogo, R.; Dupont, L.; Somers, F.; Boverie, S.; Dogné, J.-M.; Delarge, J.; Pirotte, B. Synthesis and structural studies of 3-alkylamino-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides, a new class of heterocyclic compounds with therapeutic promises. Tetrahedron 1999, 55, 5419-5432.
36. Pirotte, B.; Ouedraogo, R.; de Tullio, P.; Khelili, S.; Somers, F.; Boverie, S.; Dupont, L.; Fontaine, J.; Damas, J.; Lebrun, P. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation. J. Med. Chem. 2000, 43, 1456-1466.
37. + channels. Biochem. Pharmacol. 1994, 47, 1381-1386.
38. Boverie, S.; Antoine, M.-H.; de Tullio, P.; Somers, F.; Becker, B.; Sebille, S.; Lebrun, P.; Pirotte, B. Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino- 4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms in the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring. J. Pharm. Pharmacol. 2001, 53, 973-980.
39. 2+ channel blockers? Biol. Chem. 2002, 383, 1759-1768.
40. de Tullio, P.; Becker, B.; Boverie, S.; Dabrowski, M.; Wahl, P.; Antoine, M.-H.; Somers, F.; Sebille, S.; Ouedraogo, R.; Bondo Hansen, J.; Lebrun, P.; Pirotte, P. Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J. Med. Chem. 2003, 46, 3342-3353.
41. + channels and inhibiting insulin release. Diabetologia 2000, 43, 723-732.
42. Dabrowski, M.; Ashcroft, F. M.; Ashfield, R.; Lebrun, P.; Pirotte, B.; Egebjerk, J.; Hansen, J. B.; Whal, P. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 2002, 51, 1896-1906.
43. Flemming, E. N.; Bodvarsdottir, T. B.; Worsaae, A.; MacKay, P.; Stiden, C. E.; Boonen, H. C.; Pridal, L.; Arkhammar, P. O. G.; Whal, P.; Ynddal, L.; Junager, F.; Dragsted, N.; Tagmose, T. M.; Mogensen, J. P.; Koch, A.; Treppendahl, S. P.; Hansen, J. B. 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4- benzothiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic B-cells. J. Med. Chem. 2002, 45, 4171-4187.
44. Topliss, J. G.; Yudis, M. D. Correlation of antihypertensive activity with structure in a series of 2H-1,2,4-benzothiadiazine 1,1-dioxides using the substituent constant approach. J. Med. Chem. 1972, 15, 394-403.
45. Wales, J. K.; Krees, S. V.; Grant, A. M.; Viktoria, J. K.; Wolff, F. W. Structure-activity relationships of benzothiadiazine compounds as hyperglycemic agents. J. Pharmacol. Exp. Ther. 1968, 164, 421-432.
46. de Tullio, P.; Pirotte, B.; Somers, F.; Boverie, S.; Lacan, F.; Delarge, J. Study of the ring closure reaction of o-aminosulfonamides with 1,1′-thiocarbonyldiimidazole. Tetrahedron 1998, 54, 4935-4942.
47. Peat, A. J.; Townsend, C.; Worley, J. F.; Allen, S. H.; Garrido, D.; Mertz, R. J.; Pfohl, J. L.; Terry, C. M.; Truax, J. F.; Veasey, R. L.; Thomson, S. A. Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4- benzothiadiazine-1,1-dioxide derivatives as KATP channel agonists. Bioorg. Med. Chem. Lett. 2002, 12, 2977-2980.
48. Ashcroft, F. M.; Rosrman, P. Electrophysiology of the pancreatic B-cell. Prog. Biophys. Mol. Biol. 1989, 54, 87-143.
49. Malaisse, W. J.; Lebrun, P. Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 1990, 13, 9-17.
50. + channel openers and insulin release Life Sci. 1992, 51, 795-806.
51. 2+ influx into pancreatic B cell. Am. J. Physiol. 1982, 242, E59-E66.
52. Novelle, F. C.; Bell, S. C.; Abrams, E. L.; Ziegler, C.; Spargue, J. Diuretics: Aminobenzenedisulfonamides. J. Org. Chem. 1960, 25, 965-981.
53. Raffa, L.; Monzani, A.; Albasini, A. Halogen derivatives of 2-aminobenzenesulfonamide. Farmaco 1964, 19, 35-46.
54. Raffa, L.; Di Bella, M.; Ferrari, P.; Rinaldi, M.; Ferrari, W. Cardiovascular effect of derivatives of 1,2,4-benzothiadiazine 1,1-dioxide Farmaco 1974, 39, 411-423.
55. + channels in endocrine and smooth muscle tissues. Br. J. Pharmacol. 2001, 134, 375-385.
56. +channels and inhibition of insulin release: effect of BPDZ 62. J. Pharmacol. Exp. Ther. 1996, 277, 156-162.